275 related articles for article (PubMed ID: 36261273)
1. Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses.
Fields A; Potel KN; Cabuhal R; Aziri B; Stewart ID; Schock BC
Thorax; 2023 Aug; 78(8):799-807. PubMed ID: 36261273
[TBL] [Abstract][Full Text] [Related]
2. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
3. Performance of serum biomarkers reflective of different pathogenic processes in systemic sclerosis-associated interstitial lung disease.
Györfi AH; Filla T; Dickel N; Möller F; Li YN; Bergmann C; Matei AE; Harrer T; Kunz M; Schett G; Distler JHW
Rheumatology (Oxford); 2024 Apr; 63(4):962-969. PubMed ID: 37421394
[TBL] [Abstract][Full Text] [Related]
4. Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis.
Sakamoto N; Kakugawa T; Hara A; Nakashima S; Yura H; Harada T; Ishimoto H; Yatera K; Kuwatsuka Y; Hara T; Ichinose K; Obase Y; Ishimatsu Y; Kohno S; Mukae H
Respir Res; 2015 Dec; 16():148. PubMed ID: 26654954
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers from bronchoalveolar lavage fluid in systemic sclerosis patients with interstitial lung disease relate to severity of lung fibrosis.
Hesselstrand R; Wildt M; Bozovic G; Andersson-Sjöland A; Andréasson K; Scheja A; Westergren-Thorsson G; Bjermer L; Wuttge DM
Respir Med; 2013 Jul; 107(7):1079-86. PubMed ID: 23660398
[TBL] [Abstract][Full Text] [Related]
6. Bronchoalveoloar lavage fluid cytokines and chemokines as markers and predictors for the outcome of interstitial lung disease in systemic sclerosis patients.
Schmidt K; Martinez-Gamboa L; Meier S; Witt C; Meisel C; Hanitsch LG; Becker MO; Huscher D; Burmester GR; Riemekasten G
Arthritis Res Ther; 2009; 11(4):R111. PubMed ID: 19615053
[TBL] [Abstract][Full Text] [Related]
7. A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: A Multicenter, Observational Cohort Study.
Jee AS; Stewart I; Youssef P; Adelstein S; Lai D; Hua S; Stevens W; Proudman S; Ngian GS; Glaspole IN; Moodley YP; Bleasel JF; Macansh S; Nikpour M; Sahhar J; Corte TJ;
Arthritis Rheumatol; 2023 Aug; 75(8):1424-1433. PubMed ID: 36908055
[TBL] [Abstract][Full Text] [Related]
8. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
[TBL] [Abstract][Full Text] [Related]
9. [Use of pulmonary function tests and biomarkers studies to diagnose and follow-up interstitial lung disease in systemic sclerosis].
Hua-Huy T; Rivière S; Tiev KP; Dinh-Xuan AT
Rev Pneumol Clin; 2014 Dec; 70(6):335-42. PubMed ID: 25457218
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review.
Petelytska L; Bonomi F; Cannistrà C; Fiorentini E; Peretti S; Torracchi S; Bernardini P; Coccia C; De Luca R; Economou A; Levani J; Matucci-Cerinic M; Distler O; Bruni C
RMD Open; 2023 Nov; 9(4):. PubMed ID: 37940340
[No Abstract] [Full Text] [Related]
12. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma.
Hant FN; Ludwicka-Bradley A; Wang HJ; Li N; Elashoff R; Tashkin DP; Silver RM;
J Rheumatol; 2009 Apr; 36(4):773-80. PubMed ID: 19286849
[TBL] [Abstract][Full Text] [Related]
13. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature.
Kowal-Bielecka O; Kowal K; Highland KB; Silver RM
Semin Arthritis Rheum; 2010 Aug; 40(1):73-88. PubMed ID: 19152959
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers in systemic sclerosis-associated interstitial lung disease: review of the literature.
Bonhomme O; André B; Gester F; de Seny D; Moermans C; Struman I; Louis R; Malaise M; Guiot J
Rheumatology (Oxford); 2019 Sep; 58(9):1534-1546. PubMed ID: 31292645
[TBL] [Abstract][Full Text] [Related]
15. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
[TBL] [Abstract][Full Text] [Related]
17. Anti-Ro52 positivity is associated with progressive interstitial lung disease in systemic sclerosis-an exploratory study.
Hamberg V; Sohrabian A; Volkmann ER; Wildt M; Löfdahl A; Wuttge DM; Hesselstrand R; Dellgren G; Westergren-Thorsson G; Rönnelid J; Andréasson K
Arthritis Res Ther; 2023 Sep; 25(1):162. PubMed ID: 37667402
[TBL] [Abstract][Full Text] [Related]
18. E-Selectin, ICAM-1, and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases.
Pulito-Cueto V; Remuzgo-Martínez S; Genre F; Atienza-Mateo B; Mora-Cuesta VM; Iturbe-Fernández D; Lera-Gómez L; Mora-Gil MS; Portilla V; Corrales A; Blanco R; Cifrián JM; González-Gay MA; López-Mejías R
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569893
[TBL] [Abstract][Full Text] [Related]
19. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
[TBL] [Abstract][Full Text] [Related]
20. CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis.
Sfriso P; Cozzi F; Oliviero F; Caso F; Cardarelli S; Facco M; Fittà C; Del Rosso A; Matucci-Cerinic M; Punzi L; Agostini C
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S71-5. PubMed ID: 22691213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
